Reinforcing targeted therapeutics with phenotypic stability factors
1a Life Sciences Division ; Lawrence Berkeley National Laboratory ; Berkeley , CA USA.
Abstract:
Deregulated cell cycle progression can often be traced to intrinsic defects in specific regulatory proteins in cancer cells. Knowledge of these primary defects has led to targeted approaches that exploit the defects and spare normal cells. However, the success of such targeted approaches is still hit-or-miss. Genetic and epigenetic variability inherent in most tumors often results in phenotypic heterogeneity that, in turn, results in de novo or acquired resistance to therapeutic agents. The ability of cells to compensate and adapt to the inhibition of a specific cell cycle mediator is not remarkable. What is novel and of great potential importance is that the ability of cells to exhibit such adaptability varies markedly. "Phenotypic stability factors" that restrict the ability of cells to undergo epithelial-mesenchymal transitions (EMT) may dictate the success or failure of targeted therapies by interfering with compensatory changes such as deregulation of CDK2 activity. Identification of existing and new agents that induce and maintain phenotypic stability factors will inform and enable synergistic approaches to the eradication of even the most aggressive tumors.
Insights
Cancer cells adapt to targeted therapies due to genetic variability. Phenotypic stability factors, which limit epithelial-mesenchymal transitions (EMT), may improve targeted cancer therapy success by preventing adaptive resistance.
Area of Science:
- Oncology
- Cell Biology
- Cancer Therapeutics
Background:
- Deregulated cell cycle progression is a hallmark of cancer, often due to defects in regulatory proteins.
- Targeted therapies exploit these defects but face challenges from tumor heterogeneity and acquired resistance.
- Cancer cell adaptability to therapeutic inhibition is a critical factor in treatment outcomes.
Purpose of the Study:
- To investigate the role of phenotypic stability factors in cancer cell adaptability and therapeutic resistance.
- To explore how phenotypic stability influences compensatory mechanisms, such as cyclin-dependent kinase 2 (CDK2) deregulation.
- To identify strategies for enhancing targeted therapy efficacy against aggressive tumors.
Main Methods:
- Analysis of genetic and epigenetic variability in cancer cells.
- Assessment of phenotypic heterogeneity and its impact on treatment response.
- Investigation of epithelial-mesenchymal transitions (EMT) and their regulation by phenotypic stability factors.
- Evaluation of potential therapeutic agents that modulate phenotypic stability.
Main Results:
- Tumor cells exhibit significant variability in their ability to adapt to targeted therapies.
- Phenotypic stability factors restrict epithelial-mesenchymal transitions (EMT), influencing cellular adaptability.
- Interference with phenotypic stability can prevent compensatory changes, like CDK2 deregulation, which contribute to resistance.
- The adaptability of cells to therapeutic agents varies markedly, highlighting a novel aspect of cancer biology.
Conclusions:
- Phenotypic stability factors are critical determinants of targeted therapy success by limiting adaptive resistance mechanisms.
- Targeting agents that induce or maintain phenotypic stability could overcome therapeutic resistance in aggressive cancers.
- Understanding and manipulating phenotypic stability offers a promising avenue for developing synergistic cancer eradication strategies.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:29Pharmacogenomics: Identification of New Drug Targets
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...